Massachusetts General Hospital is pleased to announce that we are accepting applications for a joint MGH/Biogen Idec training program in translational neuroscience. The two-year, clinician scientist program is open to young neurologists who will receive an exceptional training experience for drug development, capitalizing on the expertise of those at Biogen Idec and Mass General. Applications from other institutions are encouraged.
The program objective is to train clinician-scientists to rapidly and efficiently translate advances in neuroscience into treatments for people with neurological disorders. The awardee will learn about the entire life cycle of therapy development from both industry and academic perspectives. This includes, but is not limited to, therapy selection, biomarker development, trial design, operations and regulatory science. This didactic, hands-on training program will increase the number of well-trained clinical investigators whoever passionate about drug development in the neurosciences.
Each awardee will develop a research project under the guidance of a mentoring committee that includes at least one Biogen Idec and one Mass General mentor. Awardees are expected to present their work in regular meetings and to publish results of their research in peer-review journals. Awardees will spend time at both Biogen Idec and Mass General.
The program provides annual salary support commensurate with experience plus fringe benefits. The awardee may receive additional support for course tuition, travel, computer and supplies. Additional support of his/her clinical research project may be available depending on the research project.
For more information about the program, kindly visit https://www.massgeneral.org/ne... or Download our brochure for more information about the fellowship
Applications for the position starting July 1, 2021 are due by November 1, 2020. The application must include the following:
Please submit your applications by email, in PDF format, by November 1, 2020 to Bo (Carol) Qian at [email protected]
Applications will be treated as confidential documents.
Oct 15, 2020